Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.31
IPCI's Cash to Debt is ranked lower than
76% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. IPCI: 1.31 )
Ranked among companies with meaningful Cash to Debt only.
IPCI' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: No Debt Max: No Debt
Current: 1.31
Equity to Asset 0.33
IPCI's Equity to Asset is ranked lower than
82% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IPCI: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
IPCI' s Equity to Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.78 Max: 1
Current: 0.33
-1.36
1
F-Score: 3
Z-Score: -7.43
M-Score: -4.61
WACC vs ROIC
5.48%
-3105.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -363.57
IPCI's Operating margin (%) is ranked lower than
66% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. IPCI: -363.57 )
Ranked among companies with meaningful Operating margin (%) only.
IPCI' s Operating margin (%) Range Over the Past 10 Years
Min: -9455.14  Med: -430.68 Max: -40.29
Current: -363.57
-9455.14
-40.29
Net-margin (%) -371.15
IPCI's Net-margin (%) is ranked lower than
66% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. IPCI: -371.15 )
Ranked among companies with meaningful Net-margin (%) only.
IPCI' s Net-margin (%) Range Over the Past 10 Years
Min: -5735.51  Med: -573.82 Max: -43.97
Current: -371.15
-5735.51
-43.97
ROE (%) -5299.37
IPCI's ROE (%) is ranked lower than
100% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. IPCI: -5299.37 )
Ranked among companies with meaningful ROE (%) only.
IPCI' s ROE (%) Range Over the Past 10 Years
Min: -5299.37  Med: -231.08 Max: -103.25
Current: -5299.37
-5299.37
-103.25
ROA (%) -192.23
IPCI's ROA (%) is ranked lower than
94% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. IPCI: -192.23 )
Ranked among companies with meaningful ROA (%) only.
IPCI' s ROA (%) Range Over the Past 10 Years
Min: -341.48  Med: -96.04 Max: -64.63
Current: -192.23
-341.48
-64.63
ROC (Joel Greenblatt) (%) -542.41
IPCI's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. IPCI: -542.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPCI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7955.18  Med: -599.35 Max: -235.63
Current: -542.41
-7955.18
-235.63
Revenue Growth (3Y)(%) 236.70
IPCI's Revenue Growth (3Y)(%) is ranked higher than
98% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IPCI: 236.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPCI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 236.7
Current: 236.7
0
236.7
EBITDA Growth (3Y)(%) 5.30
IPCI's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. IPCI: 5.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPCI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.7 Max: 44.9
Current: 5.3
0
44.9
EPS Growth (3Y)(%) 4.70
IPCI's EPS Growth (3Y)(%) is ranked higher than
61% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. IPCI: 4.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPCI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.3 Max: 63.9
Current: 4.7
0
63.9
» IPCI's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CYDY, AMEX:XXII, NAS:GEMP, NAS:CASI, NAS:OHRP, OTCPK:MTNB, NAS:CRME, NAS:KIN, NAS:REPH, NAS:SNSS, NAS:BDSI, NAS:CFRX, NAS:ZFGN, NAS:ONS, NAS:NVLS, OTCPK:PRMCF, NAS:TTNP, OTCPK:MCUJF, NAS:SBBP, NAS:QLTI » details
Traded in other countries:I.Canada, I4A.Germany,
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, it has developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.

Ratios

vs
industry
vs
history
Forward P/E 11.64
IPCI's Forward P/E is ranked higher than
75% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. IPCI: 11.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 44.88
IPCI's P/B is ranked lower than
97% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. IPCI: 44.88 )
Ranked among companies with meaningful P/B only.
IPCI' s P/B Range Over the Past 10 Years
Min: 6.86  Med: 14.34 Max: 551.11
Current: 44.88
6.86
551.11
P/S 26.67
IPCI's P/S is ranked lower than
69% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. IPCI: 26.67 )
Ranked among companies with meaningful P/S only.
IPCI' s P/S Range Over the Past 10 Years
Min: 6  Med: 21.42 Max: 4290
Current: 26.67
6
4290
Shiller P/E 0.20
IPCI's Shiller P/E is ranked higher than
97% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. IPCI: 0.20 )
Ranked among companies with meaningful Shiller P/E only.
IPCI' s Shiller P/E Range Over the Past 10 Years
Min: 0.03  Med: 0.06 Max: 0.46
Current: 0.2
0.03
0.46
Current Ratio 0.94
IPCI's Current Ratio is ranked lower than
89% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. IPCI: 0.94 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s Current Ratio Range Over the Past 10 Years
Min: 0.25  Med: 5.17 Max: 94.99
Current: 0.94
0.25
94.99
Quick Ratio 0.94
IPCI's Quick Ratio is ranked lower than
85% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. IPCI: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.25  Med: 5.06 Max: 94.99
Current: 0.94
0.25
94.99
Days Sales Outstanding 50.63
IPCI's Days Sales Outstanding is ranked higher than
60% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. IPCI: 50.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.5  Med: 26.16 Max: 352.81
Current: 50.63
0.5
352.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
IPCI's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. IPCI: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.7  Med: -25.2 Max: -10.6
Current: -10.6
-120.7
-10.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 44.50
IPCI's Price/Tangible Book is ranked lower than
97% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. IPCI: 44.50 )
Ranked among companies with meaningful Price/Tangible Book only.
IPCI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.02  Med: 0.59 Max: 286.67
Current: 44.5
0.02
286.67
Price/Median PS Value 1.20
IPCI's Price/Median PS Value is ranked lower than
69% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. IPCI: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
IPCI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 2.36 Max: 400
Current: 1.2
0.3
400
Earnings Yield (Greenblatt) (%) -11.97
IPCI's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. IPCI: -11.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPCI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -671.7  Med: 0 Max: 0
Current: -11.97
-671.7
0

More Statistics

Revenue (TTM) (Mil) $2.52
EPS (TTM) $ -0.37
Beta1.62
Short Percentage of Float8.45%
52-Week Range $1.41 - 3.35
Shares Outstanding (Mil)28.96

Analyst Estimate

Nov16 Nov17 Nov18 Nov19
Revenue (Mil $) 3 34 73 135
EPS ($) -0.39 0.32 1.04 2.23
EPS w/o NRI ($) -0.39 0.32 1.04 2.23
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics to Present at the LD Micro Main Event Nov 29 2016
IntelliPharmaCeutics Intl Inc (USA) (IPCI) Needs A Partner Nov 28 2016
Intellipharmaceutics Submits NDA for Pain Treatment Rexista Nov 28 2016
IntelliPharmaCeutics (IPCI) Jumps: Stock Adds 5% in Session Nov 28 2016
The FDA's Historic Caution On Abuse Deterrent Labeling Nov 25 2016
Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended... Nov 25 2016
Raging Bull Portfolio: Abeona Therapeutics Inc (ABEO) And IntelliPharmaCeutics Intl Inc (USA) (IPCI) Nov 07 2016
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher? Oct 20 2016
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference Oct 14 2016
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference Oct 14 2016
Intellipharmaceutics Announces Third Quarter 2016 Results Oct 13 2016
Intellipharmaceutics Announces Third Quarter 2016 Results Oct 13 2016
IntelliPharmaCeutics (IPCI) Jumps: Stock Moves 5.4% Higher Oct 13 2016
Intellipharmaceutics (IPCI) Stock Climbs on Licensing Agreeement Oct 12 2016
IntelliPharmaCeutics Inks New Licensing Deal With Mallinckrodt Oct 12 2016
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt Oct 11 2016
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt Oct 11 2016
Here’s Why Supernus Pharmaceuticals, Rent-A-Center and Three Other Stocks are Down Today Oct 11 2016
IntelliPharmaCeutics Soars on Tentative FDA Approval Oct 10 2016
Here’s Why Mylan, Diamondback Energy, TESARO and Two Other Stocks Are Surging Today Oct 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)